Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36210
Title: Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.
Authors: Cooray S.D.;Bahri Khomami M.;Joham A.E.;Misso M.L.;Moran L.J.;Teede H.J. ;Ranasinha S.;Harrison C.L.;Norman R.J.;Lim S.S.;Kakoly N.S.;Tan J.W.J.;Fitzgerald G.
Institution: (Lim, Kakoly, Tan, Fitzgerald, Bahri Khomami, Joham, Cooray, Misso, Harrison, Ranasinha, Teede, Moran) Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia (Joham, Cooray, Teede) Diabetes and Vascular Medicine Unit, Monash Health, Clayton, VIC, Australia (Teede) Monash Partners Academic Health Sciences Centre, Melbourne, VIC, Australia (Norman, Moran) Robinson Research Institute, University of Adelaide and Fertility SA, Adelaide, SA, Australia
Issue Date: 24-Jan-2019
Copyright year: 2019
Publisher: Blackwell Publishing Ltd
Place of publication: United Kingdom
Publication information: Obesity Reviews. 20 (2) (pp 339-352), 2019. Date of Publication: Februaryy 2019.
Journal: Obesity Reviews
Abstract: Introduction: Women with polycystic ovary syndrome (PCOS) have increased risk of metabolic syndrome. The relative contribution of clinical, demographic or biochemical factors to metabolic syndrome in PCOS is not known. A literature search was conducted in MEDLINE, CINAHL, EMBASE and clinical trial registries. Of 4530 studies reviewed, 59 were included in the systematic review and 27 in the meta-analysis and meta-regression. In good and fair quality studies, women with PCOS had an overall increased prevalence of metabolic syndrome (odds ratio, OR 3.35, 95% confidence interval, CI 2.44, 4.59). Increased prevalence of metabolic syndrome occurred in overweight or obese women with PCOS (OR 1.88, 95% 1.16, 3.04) but not in lean women (OR 1.45, 95% CI 0.35, 6.12). In meta-regression analyses, the markers of metabolic syndrome diagnostic criteria (waist circumference, high-density lipoprotein cholesterol, triglyceride, blood pressure), BMI, glucose tolerance (2-hr oral glucose tolerance test) and surrogate markers of insulin resistance (HOMA-IR) but not markers of reproductive dysfunction (sex hormone binding globulin, testosterone, PCOS phenotypes) contributed significantly to the heterogeneity in the prevalence of metabolic syndrome. Women with PCOS have increased risk of metabolic syndrome which was associated with obesity and metabolic features but not with indices of hyperandrogenism.Copyright © 2018 World Obesity Federation
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/obr.12762
PubMed URL: 30339316 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30339316]
ISSN: 1467-7881
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/36210
Type: Review
Type of Clinical Study or Trial: Systematic review and/or meta-analysis
Appears in Collections:Articles

Show full item record

Page view(s)

44
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.